| AP26113 |
| 5-Chloro-N2-{4-[4-(dimethylamino)-1-piperidinyl]-2-methoxyphenyl}-N4-[2-(dimethylphosphoryl)phenyl]-2,4-pyrimidinediamine |
| (CAS 1197958-12-5) |
 |
| Description： |
AP26113 is an investigational small-molecule targeted cancer therapy being developed by ARIAD Pharmaceuticals, Inc. AP26113 has exhibited activity as a potent dual inhibitor of anaplastic lymphoma kinase (ALK) and epidermal growth factor receptor (EGFR). This compound targets a unique genetic feature of cancer cells and ARIAD has begun a Phase 1/2 clinical trial of AP26113 based on patients’ molecular diagnoses in September 2011.
|
| Product No. |
KT00086 |
| Product Name |
AP26113 |
| Synonyms |
|
| Formal Name |
5-Chloro-N2-{4-[4-(dimethylamino)-1-piperidinyl]-2-methoxyphenyl}-N4-[2-(dimethylphosphoryl)phenyl]-2,4-pyrimidinediamine |
| CAS Number |
1197958-12-5 |
| Molecular Formula |
C26H34ClN6O2P |
| Formula Weight |
529.01 |
| Formulation |
A crystalline solid |
| Purity |
98%min |
| Stability |
2 years |
| Storage |
-20°C |
| Shipping |
USD45 for Europe and USA. No shipping charge once amount reach USD500 |
| Quality Control |
HNMR,CNMR,LCMS,HPLC,IR,etc. |
| Price & Availability |
In Stock. Price Negotiated. |
|
| Related Products： |
ALK inhibitor 1
ALK inhibitor 2
ASP3026
AZD-3463
CEP-37440
CH5424802
DMH-1
|
|
